Medical Research Agency

 $https://abm.gov.pl/en/news/165, Calendar-of-calls-carried-out-and-planned-to-be-carried-out-by-the-Medical-Resea. html \\03.07.2024, 10:09$

Calendar of calls carried out and planned to be carried out by the Medical Research Agency

Calendar of calls carried out and planned to be carried out by the Medical Research Agency

| | Caleridar of Calls Carried out and planned to be Carried out by the Medicar Research Agency | | | | | | |
|-----|--|---------------------|------------------------|--|--|--|--|
| no. | Name of the call | Amount [million] | Implementation mode | Deadline for the announcement of call | | | |
| 1 | Open call for non-commercial clinical trials - 2022 edition. ABM/2022/1 | 200 mln PLN | call | First round - 1st quarter of 2022. Second round - 2nd quarter 2022. | | | |
| 2 | Call for enterprises for funding the development, performance evaluation, clinical evaluation of innovative medical devices ABM/2022/2 | 100 mln PLN | call | 1st quarter of 2022. | | | |
| 3 | Call for proposals for the design and development of innovative solutions in the area of new pharmaceutical forms and development of technologies of active substances of authorised medicinal products (generics) and biosimilar medicines. ABM/2022/4 | 150 mln PLN | call | 2nd quarter of 2022. | | | |
| 4 | Call for non-commercial clinical trials assessing the clinical and cost effectiveness of different medicinal products in the same indication - head-to-head studies. ABM/2022/3 | 100 mln PLN | call | 3rd quarter of 2022 | | | |
| 5 | Development of targeted or personalised medicine based on cell therapies or protein products ABM/2022/5 | 250 mln PLN | call | 3rd quarter of 2022 | | | |
| 6 | Development of targeted or personalised medicine based on nucleic acid-based medicinal products. ABM/2022/6 | 250 mln PLN | call | 4th quarter of 2022 | | | |
| 7 | Call for enterprises to develop innovative medical devices based on artificial intelligence to coordinate diagnosis and treatment in outpatient specialist care and hospital treatment. ABM/2022/7 | 30 mln PLN | call | 4th quarter of 2022 | | | |